GlassScriptPhysician profile
Robert M Dermarkarian
NPI 1770675530
$105,219.77
in general payments reported to CMS, 2019-2025
48 companies · $25K in 2025
The $25K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,146 · 2021: $1,718 · 2022: $8,203 · 2023: $28K · 2024: $29K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Food and Beverage: $10K · Travel and Lodging: $3,712 · Consulting Fee: $2,704 · Education: $84.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,350.00 |
| Food and Beverage | $10,337.98 |
| Travel and Lodging | $3,711.91 |
| Consulting Fee | $2,704.00 |
| Education | $84.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $80,009.56 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Janssen Pharmaceuticals, INC | $10,141.05 | 2019-2022 | |
| Roche Diagnostics Corporation | $2,704.00 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $2,360.75 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Glaxosmithkline, LLC. | $1,150.05 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $844.27 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $703.31 | 2021-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $690.24 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Grifols USA, LLC | $591.92 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $574.70 | 2020-2025 | Dupixent |
| Philips North America LLC | $504.95 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $495.90 | 2022-2025 | Glassia |
| Amgen INC. | $474.29 | 2019-2025 | Tezspire |
| Mylan Specialty L.P. | $437.92 | 2019-2024 | Yupelri |
| Electromed, INC. | $358.17 | 2021-2025 | Smartvest |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $346.29 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $320.83 | 2020-2025 | Acthar |
| Baxter Healthcare | $255.02 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Mallinckrodt Enterprises LLC | $231.39 | 2019 | |
| Genzyme Corporation | $203.81 | 2021-2025 | |
| Verona Pharma, INC. | $203.32 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $163.62 | 2023-2025 | Winrevair, Keytruda |
| Medtronic USA, INC. | $149.30 | 2020 | |
| Boston Scientific Corporation | $132.25 | 2023 | Watchman Access System |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $112.42 | 2021-2025 | |
| Pfizer INC. | $83.73 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $83.15 | 2019-2023 | Nuzyra |
| Vifor Pharma, INC. | $77.76 | 2024-2025 | Zemaira |
| Pulmonx Corporation | $69.21 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Jazz Pharmaceuticals INC. | $65.88 | 2021 | |
| Melinta Therapeutics, LLC | $64.69 | 2021 | |
| Inogen, INC. | $57.90 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $56.40 | 2019-2020 | |
| Novo Nordisk INC | $44.79 | 2021-2025 | Ozempic, Rybelsus |
| Advanced Respiratory, INC | $43.24 | 2020 | |
| Ani Pharmaceuticals, INC. | $32.60 | 2023 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $31.58 | 2020-2022 | |
| Amarin Pharma, INC. | $27.73 | 2021 | |
| Cmp Pharma, INC. | $27.64 | 2024 | Norliqva, Carospir, Atorvaliq |
| Teva Pharmaceuticals USA, INC. | $26.04 | 2020-2021 | |
| Veran Medical Technologies, INC. | $25.98 | 2020-2021 | |
| Inspire Medical Systems, INC. | $25.94 | 2024 | Inspire |
| Horizon Therapeutics Plc | $24.66 | 2020 | |
| Resmed Corp | $19.66 | 2022 | |
| Olympus America INC. | $18.96 | 2021 | |
| Astellas Pharma US INC | $16.30 | 2022 | |
| Shire North American Group INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dermarkarian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.